Connect with others who understand.

sign up log in
Resources
About myPHteam
Powered By

FDA Approves Ketamine-Like Drug for Severe Depression

Posted on March 18, 2019

By Carole Tanzer Miller and E.J. Mundell, HealthDay Reporters

WEDNESDAY, March 6, 2019 (HealthDay News) -- The U.S. Food and Drug Administration approved the nasal spray medication esketamine -- a relative of the club drug and anesthetic ketamine -- for use against severe depression.

Sold as Spravato, the fast-acting drug becomes the first new type of medicine approved in years against an illness that plagues millions of Americans.

In a statement, the FDA said Spravato should be used in conjunction with an antidepressant pill and is meant only for people whose depression has not responded to at least two other antidepressants.

Spravato -- a much less potent relative of the illicit club drug "Special K" -- comes with other restrictions, the FDA said. Ketamine can induce dissociation (feeling disconnected from one's surroundings) and sedation.

Because Spravato might act similarly for a minority of patients, the FDA said safeguards are warranted.

"Because of safety concerns, the drug will only be available through a restricted distribution system and it must be administered in a certified medical office where the health care provider can monitor the patient," said Dr. Tiffany Farchione. She's acting director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research.

Patients will self-administer the nasal spray during visits to a medical clinic, and the spray cannot be taken home. A health care provider will monitor the patient until it is clear that he or she is ready to leave.

Ketamine came first

Approval of a medicine like Spravato is welcome news for patients like Jen Godfrey, who said she couldn't shake the "deep cloud" of depression that lingered even after she found an antidepressant she could tolerate. She turned to clinics that were dispensing the anesthetic ketamine "off-label" for help against depression.

A number of stressors had hit Godfrey hard -- five years of fertility treatment and an 80-pound weight gain during pregnancy that left her with persistent pain; a close relative's suicide; another who went missing; and her own divorce. It was all too much.

"The life stuff just had a gravitational pull," said the stay-at-home mom from Reno, Nev., who's in her mid-40s. "I just thought: I don't drink, I'm a good friend, a good mother, a good spouse -- I should be a lot happier."

Godfrey's search for relief pointed her towards ketamine. Low, intravenous doses have been found to boost mood and curb suicidal thoughts, but the FDA has never approved ketamine as a treatment for depression. And the American Psychiatric Association (APA) warns patients about the potential for abuse and the lack of large, long-term studies of its effectiveness.

Even so, ketamine clinics like the one treating Godfrey have sprung up across the United States.

"The lack of information [on ketamine] is really quite dramatic when you look at the proliferation of use in certain communities," said former APA President Dr. Alan Schatzberg. He helped write an APA statement about ketamine urging caution.

A new, safer alternative?

Spravato, the drug approved Tuesday, is touted as a much safer cousin of ketamine.

Speaking this week with National Public Radio, Courtney Billington, president of Janssen Neuroscience, said that, unlike ketamine, "the amount of active ingredient that's in this product is at a very, very low dose."

In four studies that led to its approval, Spravato performed well against placebo, the FDA said, showing a "statistically significant effect compared to placebo on the severity of depression, and some effect was seen within two days." That's a much faster time to symptom relief than many antidepressants.

One longer-term trial suggests that Spravato's benefit lasts, the FDA said.

Side effects can occur, however.

"The most common side effects experienced by patients treated with Spravato in the clinical trials were dissociation, dizziness, nausea, sedation, vertigo, decreased feeling or sensitivity (hypoesthesia), anxiety, lethargy, increased blood pressure, vomiting and feeling drunk," the agency said.

Because of these potential effects, people with high blood pressure or certain vascular disorders should not take Spravato, and people should get a night of "restful sleep" before attempting to drive after taking the drug.

Also, "Spravato may cause fetal harm and women of reproductive potential should consider pregnancy planning and prevention; women should not breastfeed while being treated," the FDA said.

A 'game-changer'

How do medicines like Spravato and ketamine help ease depression?

It's not clear, Schatzberg said. One common theory is that they affec the brain's response to the neurotransmitter glutamate. Neurotransmitters are chemicals that send signals from one part of the brain to another and from the brain to the body. Essentially, the thinking goes, these meds rewire the brain.

But Schatzberg, a professor of psychiatry and behavioral sciences at Stanford University, was part of a small study published online recently in The American Journal of Psychiatry. It suggested another explanation -- that ketamine somehow activates opioid receptors in the brain.

That's potentially troubling, he said.

"We could be exposing people to untoward consequences from a drug that works through an opioid mechanism," he said. With an opioid addiction crisis in full swing across the United States, "we need to study [ketamine] more," he added.

For her part, Godfrey said ketamine has been nothing short of a miracle for her. Before that, she had tried a series of antidepressants before finding one that helped a bit, and everything from acupuncture to yoga and meditation. But her gloom and pain never seemed to go away.

"I did not think that anything with this much relief and promise would come along in my lifetime, let alone now," Godfrey said. "It's a game-changer."

SOURCES: Jen Godfrey, Reno, Nev.; Alan Schatzberg, M.D., professor, psychiatry and behavioral sciences, Stanford University, Stanford, Calif., and former president, American Psychiatric Association; Robert Watson, M.D., owner, Sierra Ketamine Clinics, Reno, Nev.; U.S. Food and Drug Administration, news release, March 5, 2019; National Public Radio

Copyright © 2019 All rights reserved.

What do you think about this new treatment for depression? Share in the comments below!

 
All updates must be accompanied by text or a picture.

Related articles

Treating PAH with two or more therapies, known as combination therapy, is an effective way to...

Finding the Best PAH Treatment: What Is Combination Therapy?

Treating PAH with two or more therapies, known as combination therapy, is an effective way to...
Endothelin is a small protein in the blood that helps regulate blood pressure. High levels of...

Endothelin and Pulmonary Arterial Hypertension: 6 Things To Know

Endothelin is a small protein in the blood that helps regulate blood pressure. High levels of...
Whether you’ve been on combination therapy or are just starting it for pulmonary arterial...

5 Questions To Ask Your Doctor About PAH Combination Therapy

Whether you’ve been on combination therapy or are just starting it for pulmonary arterial...
Pulmonary arterial hypertension (PAH) is high blood pressure of the arteries that take blood from...

Finding the Best PAH Treatment: 6 Facts To Know

Pulmonary arterial hypertension (PAH) is high blood pressure of the arteries that take blood from...
Following a healthy diet benefits everyone, but it can be especially important for managing the...

Diet and Pulmonary Arterial Hypertension: What To Eat and What To Avoid

Following a healthy diet benefits everyone, but it can be especially important for managing the...
Risk assessment is an important part of treating and managing pulmonary arterial hypertension...

5 Questions To Assess Your Risk With PAH

Risk assessment is an important part of treating and managing pulmonary arterial hypertension...

Recent articles

Rosetta is a 35-year-old woman living with idiopathic pulmonary arterial hypertension (iPAH). She...

My Life With PAH

Rosetta is a 35-year-old woman living with idiopathic pulmonary arterial hypertension (iPAH). She...
Early on, pulmonary arterial hypertension (PAH) doesn’t typically cause symptoms. However, many...

PAH and Swelling: 10 Things To Know

Early on, pulmonary arterial hypertension (PAH) doesn’t typically cause symptoms. However, many...
When a person has high blood pressure in the blood vessels running from their heart to their...

Prostacyclin and Pulmonary Arterial Hypertension: 6 Things To Know

When a person has high blood pressure in the blood vessels running from their heart to their...
Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH) caused by the...

6 Medical Specialists You Need on Your PAH Care Team

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension (PH) caused by the...
Living with pulmonary arterial hypertension (PAH) can make everyday tasks and activities...

9 Tips for Living With PAH

Living with pulmonary arterial hypertension (PAH) can make everyday tasks and activities...
Risk assessment for pulmonary arterial hypertension (PAH) helps monitor disease progression and...

PAH Risk Assessment: How Doctors Predict Progression

Risk assessment for pulmonary arterial hypertension (PAH) helps monitor disease progression and...
myPHteam My pulmonary hypertension Team

Thank you for subscribing!

Become a member to get even more:

sign up for free

close